Brain Aneurysm Clinical Trial
— AWARDOfficial title:
Adjunctive Wide-neck Aneurysm Reconstruction Device Post Market Clinical Study Europe
Verified date | February 2019 |
Source | Pulsar Vascular |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a prospective multi-center, single arm, non-randomized study. It is designed to evaluate the safety of the PulseRider® in patients undergoing treatment for bifurcation intracranial aneurysms.
Status | Completed |
Enrollment | 35 |
Est. completion date | December 31, 2018 |
Est. primary completion date | December 31, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Patient who presents with an MRA, CTA or angiographically confirmed, wide neck (> 4 mm or dome to neck ratio < 2) intracranial aneurysms located at a bifurcation 2. The target aneurysm is in a vessel with a diameter of 2.7 mm to 4.5mm. 3. The patient is 18 years or older at the time of consent 4. The patient has signed the IRB/EC approved informed consent form 5. In the opinion of the physician, placement of the PulseRider is technically feasible and clinically indicated 6. Subject has mental capacity and is willing and able to comply with protocol requirements and follow-up Exclusion Criteria: 1. Unstable neurological deficit (condition worsening within the last 90 days) 2. Subarachnoid Hemorrhage (SAH) within the last 60 days 3. Irreversible bleeding disorder 4. mRS score =3 5. Patient has another aneurysm which, in the Investigator's opinion, will require treatment within the follow up period (365 days) 6. Platelet count < 100 x 103 cells/mm3or known platelet dysfunction 7. Inability to tolerate, adverse reaction or contraindication to taking aspirin or clopidogrel 8. A history of contrast allergy that cannot be medically controlled 9. Known allergy to nickel 10. Relative contraindication to angiography (e.g., serum creatinine > 2.5 mg/dL) 11. Woman with child-bearing potential who cannot provide a negative pregnancy test 12. Evidence of active infection (fever with temperature > 38°C and/or WBC > 15,000) 13. Other conditions of the heart, blood, brain or intracranial vessels that carry a high risk of neurologic events 14. Evidence of disease or condition expected to compromise survival or ability to complete follow-up assessments during the 365-day follow-up period 15. Extracranial stenosis greater than 50% in the parent artery requiring access to the lesion 16. Intracranial stenosis greater than 50% in the treated vessel 17. Extreme vessel tortuosity that prohibits appropriate control of the micro-guide wire and/or the PulseRider delivery wire |
Country | Name | City | State |
---|---|---|---|
Austria | Paracelsus Medical University Salzburg | Salzburg |
Lead Sponsor | Collaborator |
---|---|
Pulsar Vascular |
Austria,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety: Death or stroke in downstream territory | to 180-days post-procedure | ||
Primary | Technical Success | Device placement success and ability to retain coils within the aneurysm | at the time of the procedure | |
Primary | Rate of aneurysm occlusion | Day zero (within 24 hours post procedure) and 180-days | ||
Secondary | Rate of aneurysm occlusion | at 365-days follow-up | ||
Secondary | Device movement or migration defined as any relative change in the position of the device with respect to the parent and/or daughter vessels that is greater than 2mm by conventional catheter angiography, MRA or CTA | at 180-days follow-up and 365-days follow-up | ||
Secondary | Stenosis, defined as >50% at implant site by MR angiography or conventional catheter angiography or CTA | at 180-days follow-up and 365-days follow-up | ||
Secondary | Rate of incidence of new neurological deficits | from the time of the procedure to the 365-follow up visit | ||
Secondary | Complication rate (neurological and non-neurological) | from the time of the procedure to the 365-follow up visit |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02345395 -
Safety Study of Minimally Invasive Approaches to Unruptured Anterior Circulation Aneurysms
|
N/A | |
Active, not recruiting |
NCT05626504 -
Outcome Study of the Pipeline Embolization Device With Vantage Technology in Unruptured Aneurysms
|
||
Completed |
NCT01716117 -
Safety and Effectiveness of an Intracranial Aneurysm Embolization System for Treating Large or Giant Wide Neck Aneurysms
|
N/A | |
Completed |
NCT04439760 -
Superior Cervical Ganglion Block, Transcranial Doppler
|
N/A | |
Completed |
NCT04553549 -
Safety and Feasibility of the Infinity Catheter for Radial Access
|
||
Completed |
NCT01975233 -
WEB French Observatory of the WEB Aneurysm Embolization System
|
||
Terminated |
NCT01557036 -
Aneurysm Study of Pipeline in an Observational Registry
|
N/A | |
Completed |
NCT03844334 -
CLinical EValuation of WEB 0.017 Device in Intracranial AneuRysms
|
||
Active, not recruiting |
NCT03852680 -
Current Treatment Modalities for Wide Necked Intracranial Aneurysms
|
N/A | |
Completed |
NCT01444664 -
Aneurysm Wall Histology Registry
|
Phase 4 | |
Recruiting |
NCT03936647 -
The RISE Trial: A Randomized Trial on Intra-Saccular Endobridge Devices
|
N/A | |
Completed |
NCT02687607 -
CLARYS: CLinical Assessment of WEB® Device in Ruptured aneurYSms
|
||
Withdrawn |
NCT02037932 -
Hydrogel Balloon Assisted Intracranial Aneurysm Coiling Registry
|
Phase 4 | |
Recruiting |
NCT06456814 -
Epidemiological Insights Into the Formation, Progression, and Rupture of Intracranial Aneurysms: A Retrospective, Multi-Center Hospital-Based Study in China
|
||
Recruiting |
NCT05317169 -
Aneurysm Genetic Risk in Patients With QIB Changes
|
||
Terminated |
NCT00537134 -
Trial on Endovascular Aneurysm Management
|
N/A |